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NFATc1 is necessary for remodeling endocardial cushions into mature heart valve leaflets and is also an essential effector of receptor activator
of NFκB ligand (RANKL) signaling required for transcriptional activation of bone matrix remodeling enzymes during osteoclast differentiation.
Therefore, developing heart valves were examined to determine if NFATc1 functions in the RANKL pathway during leaflet remodeling. Key
components of RANKL signal transduction including RANKL, its receptor RANK, and the downstream remodeling enzyme cathepsin K (Ctsk) are
expressed in the heart during valve remodeling and colocalize with NFATc1 in developing valve endocardium. However, the absence of tartrate-
resistant acid phosphatase (TRAP) activity and the lack of F4/80-positive macrophage lineage contribution to the remodeling valves demonstrate
that certain aspects of osteoclast RANKL function are not shared during valve formation. Analysis of NFATc1−/− mouse embryos shows that
NFATc1 is specifically required for endocardial expression of RANKL and Ctsk during valve formation. In addition, RANKL treatment augments
expression of NFATc1 and Ctsk in embryonic heart cultures, and the RANKL-mediated increase in Ctsk expression is dependent on NFATc1.
Together, these results support a role for RANKL signaling during heart valve development and suggest that valve leaflet morphogenesis involves
NFATc1-dependent expression of remodeling enzymes including Ctsk.
© 2006 Elsevier Inc. All rights reserved.Keywords: NFATc1; RANKL; Cathepsin K; Heart valveIntroduction
Heart valve morphogenesis is a complex developmental
process required for proper cardiac function, however, the
molecular mechanisms that govern valve formation are
incompletely understood. Heart valve development begins
with the formation of valve precursors, termed endocardial
cushions, in the outflow tract and atrioventricular canal
(Schroeder et al., 2003; Wessels and Sedmera, 2003). The
cushions are formed from localized swellings of extracellular
matrix that become populated by endocardial cells that have
undergone an epithelial to mesenchymal transformation (EMT).
Subsequently, the endocardial cushions are extensively remo-
deled to form the mature semilunar (aortic and pulmonary) and
atrioventricular (mitral and tricuspid) valve leaflets (Barnett and⁎ Corresponding author. Fax: +1 513 636 5958.
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doi:10.1016/j.ydbio.2006.01.017Desgrosellier, 2003). Whereas several molecular regulators of
endocardial cushion formation and EMT have been identified
(Person et al., 2005), the mechanisms that control extracellular
matrix remodeling during heart valve leaflet formation are not
well defined.
The calcineurin/NFATc1 signaling pathway was among the
first implicated in heart valve maturation with the observation
that the endocardial cushions fail to remodel into valve leaflets
in NFATc1−/− mice (de la Pompa et al., 1998; Ranger et al.,
1998). Calcineurin, a serine/threonine phosphatase composed of
a regulatory calcineurin B (CnB) subunit and a catalytic
calcineurin A (CnA) subunit, is activated in response to
sustained elevation of intracellular Ca2+ levels (Klee et al.,
1998). Transcription factors of the NFATc family (c1–c4) are
substrates of activated calcineurin that, upon dephosphoryla-
tion, translocate to the nucleus to regulate expression of target
genes in cooperation with transcriptional cofactors (Crabtree
and Olson, 2002; Hogan et al., 2003). In mice, homozygous
null mutation of NFATc1 or endothelial-specific deletion of
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day (E)13.5 due to defects in valve formation (Chang et al.,
2004; de la Pompa et al., 1998; Ranger et al., 1998). Although
endocardial cushion formation and EMT are initiated in both
models, the semilunar and AV valves are hypoplastic and fail to
remodel intomature leaflets (Changetal.,2004;de laPompaetal.,
1998; Ranger et al., 1998). Therefore, calcineurin/NFATc1
signaling during valve morphogenesis is not necessary for
EMT (E8.5–E10.5) but is required for remodeling of the
endocardial cushions into mature leaflets (E11+). In adult
human pulmonary valve endothelial cells, calcineurin/NFATc1
signaling regulates cell proliferation in response to VEGF
(Johnson et al., 2003). The limited number of NFATc1
transcriptional targets in cardiac endothelial cells that have been
identified includes the vasoconstrictor endothelin-1 (ET-1) and
the calcineurin regulatory proteinDown syndrome critical region
1 (DSCR1) (Lange et al., 2004;Nemer andNemer, 2002).Despite
these advances, themechanism bywhichNFATc1 regulates heart
valve remodeling in relation to upstream activators and
downstream transcriptional targets has remained elusive.
In addition to its essential role in valve development,
NFATc1 also is a critical transcriptional effector of RANKL-
mediated osteoclast differentiation (Hirotani et al., 2004;
Ishida et al., 2002; Takayanagi et al., 2002). RANKL, a
member of the TNF ligand family, is a key factor for
osteoclastogenesis and signals through its receptor RANK to
promote differentiation of bone resorbing osteoclasts (Hsu et al.,
1999; Lacey et al., 1998; Nakagawa et al., 1998). RANKL
signaling is negatively regulated by a soluble decoy receptor
osteoprotegerin (OPG), which binds RANKL to prevent its
interaction with RANK (Simonet et al., 1997; Yasuda et al.,
1998a,b). In addition to osteoclasts, the RANKL pathway also
has roles in vascular endothelial cells as well as T-cells and
dendritic cells of the immune system (Collin-Osdoby, 2004;
Theoleyre et al., 2004; Walsh and Choi, 2003). During
osteoclast differentiation, RANKL strongly induces NFATc1
gene expression as well as sustained Ca2+ oscillations
necessary for calcineurin-mediated activation of NFATc1
protein (Day et al., 2004; Hirotani et al., 2004; Ishida et al.,
2002; Takayanagi et al., 2002; Zhu et al., 2005). Furthermore,
osteoclast differentiation is impaired in NFATc1 deficient cells
or by pharmacological inhibition of calcineurin activity, and
expression of NFATc1 is sufficient to promote osteoclasto-
genesis in the absence of RANKL (Hirotani et al., 2004;
Ikeda et al., 2004; Ishida et al., 2002; Matsuo et al., 2004;
Takayanagi et al., 2002). In addition, tartrate-resistant acid
phosphatase (TRAP/Acp5) and the cysteine protease cathepsin
K (Ctsk) are among the downstream targets of NFATc1 in
differentiating osteoclasts (Ikeda et al., 2004; Matsumoto et al.,
2004; Matsuo et al., 2004; Takayanagi et al., 2002). While
activators of NFATc1, including RANKL, and transcriptional
targets, such as TRAP and Ctsk, have been defined in bone, this
pathway has not been previously implicated in heart valve
development. Therefore, to gain insight into the regulatory
functions of NFATc1 in heart valve formation, the relationship
between RANKL signaling and NFATc1 during valve leaflet
remodeling was examined.Materials and methods
Mice
NFATc1 gene targeted mice were obtained from Dr. Laurie Glimcher, and
PU.1 heterozygous mice were a gift from Dr. Richard Lang (McKercher et al.,
1996; Ranger et al., 1998). Heterozygous intercrosses were established for timed
matings with the presence of a copulation plug in the morning representing
embryonic day (E)0.5. Genotypes were determined by PCR using yolk sac DNA
as previously described (McKercher et al., 1996; Ranger et al., 1998).
RT-PCR
Total RNA was isolated from whole E11.5–E14.5 hearts and E14.5
forelimbs using Trizol reagent (Life Technologies), and cDNA was generated
with oligo(dT) primers and the SuperScript First-Strand Synthesis kit
(Invitrogen). RT-PCR reactions for E11.5–E14.5 hearts were performed at 30
cycles. Quantitative real time RT-PCR was performed using the MJ Research
Opticon Monitor II system. Real time RT-PCR analysis of Ctsk andMmp2 gene
expression in hearts from NFATc1 targeted mice was repeated three times using
technical duplicates from three independent samples from each genotype. PCR
reactions (95°C, 30 s; 64°C, 30 s; 72°C, 30 s; 35 cycles) included 0.1× Sybr
Green (Molecular Probes), and fluorescence was monitored at 72°C. Gene
expression levels were quantified based on threshold cycle [C(t)] calibrated to a
standard curve and normalized to L7 as previously described (Lange et al.,
2005). Primer sequences and annealing temperatures are listed in Table 1.
Statistical significance of observed differences was determined by two-tailed
Student's t test.
In situ hybridization
Sequences used to analyze gene expression by in situ hybridization were
amplified by RT-PCR using E13.5 mouse heart cDNA, subcloned into pGEM
T-vector (Promega), and confirmed by sequencing (see Table 1) or have been
previously described (Lange et al., 2004). Digoxigenin-labeled antisense RNA
probes were generated from linearized plasmids using SP6 polymerase
(Promega) or T7 polymerase (Roche). Embryos were isolated at E11.5–
E14.5 and fixed overnight in 4% paraformaldehyde/PBS at 4°C. Forelimbs
were dissected from E13.5 to E14.5 embryos and processed in parallel. After
fixation, embryos and forelimbs were infiltrated with sucrose and embedded in
OCT. Non-radioactive in situ hybridization was performed on cryosections
(12–14 μm) as previously described (Lange et al., 2004). Sections were
mounted using Cytoseal (Electron Microscopy Science), and images were
obtained using an Olympus BX60 microscope equipped with a Spot 3.0.4
digital camera.
Enzyme histochemistry
Mouse embryos were harvested at E13.5 or E15.5, rinsed in PBS, and snap-
frozen unfixed in OCT for cryosectioning. Endogenous acid phosphatase or
tartrate-resistant acid phosphatase enzyme activity was assessed on 7–10 μm
sections using the leukocyte acid phosphatase kit (Sigma) according to the
manufacturer's instructions. Counterstaining was omitted, and sections were
mounted in aqueous media.
Immunofluorescence
Cryosections (5 μm) of fixed, OCT embedded embryos and forelimbs were
used for immunofluorescent analysis of localized protein expression. Sections
were rinsed in PBS to remove OCT, and microwave antigen retrieval was
performed with Vector Unmasking Solution (Vector Labs) for NFATc1 or with
0.1 M glycine/PBS, pH 3.5 for Ctsk and F4/80. Sections were then rinsed in
PBST (1× PBS, 0.1% Tween 20) and blocked for 1 h (2% serum from secondary
antibody host species, 2% BSA, 0.1% NP-40). Primary antibody incubation was
performed overnight at 4°C in blocking solution with mouse anti-NFATc1
(1:100, Santa Cruz), goat anti-cathepsin K (1:150, Santa Cruz), or rat anti-F4/80
(1:150, Abcam). Sections were then rinsed in PBST and incubated with
Table 1
Oligonucleotide sequences
Gene (accession #) Product length (bp) Annealing
temperature (°C)
Oligonucleotide sequences
RT-PCR a
RANKL (NM011613) 750 62 ATCAGAAGACAGCACTCACT
ATCTAGGACATCCATGCTAATGTTC
RANK (NM009399) 819 59 TCCTGGGCTTCTTCTCAGAT
GGAGGCAACTGTCACCTTCT
Ctsk (NM007802) 824 52 TCTCTCGGCGTTTAATTTGG
GCAGGCGTTGTTCTTATTCC
Mmp2 (NM008610) 681 62 GACATCAAGGGGATCCAGGAGCTC
TCAGCAGCCCAGCCAGTCTGATTTG
Real time RT-PCR
NFATc1 (NM016791) 190 64 CGGGAAGAAGATGGTGCTGT
TTGGACGGGGCTGGTTAT
Ctsk 174 64 CAGCAGAGGTGTGTACTATG
GCGTTGTTCTTATTCCGAGC
Mmp2 145 64 TTCCCCCGCAAGCCCAAGTG
GAGAAAAGCGCAGCGGAGTGACG
a Sequences amplified with these oligonucleotides were subcloned and used to generate antisense probes for in situ hybridization.
409A.W. Lange, K.E. Yutzey / Developmental Biology 292 (2006) 407–417secondary antibodies for 1 h at room temperature. Secondary antibodies were
used at 1:200 in blocking solution and included goat anti-mouse Alexa Fluor
568, rabbit anti-goat Alexa Fluor 488, and goat anti-rat Alexa Fluor 488
(Molecular Probes). Following secondary antibody incubation, sections were
rinsed and mounted with Vectashield Hard Set (Vector Labs). Fluorescent
microscopy was performed using a Nikon PCM 2000 confocal microscope, and
images were obtained with Simple PCI software.
Whole heart organ cultures
Whole heart organ cultures were established as described by Rentschler et al.
(2002). Nontransgenic or NFATc1 heterozygous intercrosses were established,
and embryos were harvested at E10.5. Embryonic hearts were isolated and
cultured in 24-well plates for 24 h at 37°C in DMEM containing 1% fetal bovine
serum and penicillin/streptomycin (Gibco, 100 units/ml). Culture media was
further supplemented with 100 ng/ml recombinant human RANKL (rhRANKL;
R&D Systems) or 0.1% BSA for vehicle controls, and media was replaced at
12 h. All embryonic hearts obtained from NFATc1 heterozygous crosses were
cultured in the presence of rhRANKL, and genotypes were determined by PCR
using genomic DNA during the 24 h culture period. At 24 h, hearts were rinsed
in PBS and two hearts from each experimental condition were pooled for RNA
extraction as described above. Real time RT-PCR analysis was repeated six
times using three independent pooled samples from each condition, and
statistical significance was determined using a one-tailed Student's t test. Linear
range RT-PCR was performed for NFATc1, Ctsk, and L7 (24, 30, and 22 cycles,
respectively) gene expression in cultured hearts, and amplification products
were analyzed on ethidium bromide gels. Alternatively, cultured hearts were
fixed and embedded in OCT as previously described. Serial cryosections (5 μm)
were analyzed by immunofluorescence for NFATc1 or in situ hybridization for
NFATc1 and Ctsk as detailed above.Fig. 1. Components of the RANKL pathway are expressed in the embryonic
heart during stages of heart valve remodeling. Expression of genes in the
RANKL signaling pathway was examined by RT-PCR of cDNA generated from
E11.5–E14.5 mouse embryo whole hearts. RANKL, RANK, Ctsk, and Mmp2
gene expression is detected in embryonic hearts during early stages of valve
remodeling. E14.5 forelimbs and no RT samples were included as positive and
negative controls, respectively. L7 expression was included as a loading control.
FL, forelimb.Results
Components of the RANKL signaling pathway are
co-expressed in the remodeling heart valves
Embryonic hearts were examined during early stages of heart
valve remodeling for cardiac expression of genes associated
with RANKL signal transduction. Transcripts for RANKL and
its receptor RANK are detected in embryonic hearts betweenE11.5 and E14.5 by RT-PCR, demonstrating that genes
involved in RANKL pathway activation are expressed in the
developing heart (Fig. 1). In addition, embryonic hearts show
strong expression of Ctsk, a potent matrix degrading protease
and known target of RANKL signaling in osteoclasts, and
Mmp2, an extracellular matrix metalloproteinase implicated in
EMT during cushion formation (Fig. 1) (Alexander et al., 1997;
Song et al., 2000). Notably, these genes are all expressed at
significant levels in the heart at E13.5, a critical stage at which
valve defects due to targeted inactivation of NFATc1 result in
embryonic lethality (Chang et al., 2004; de la Pompa et al.,
1998; Ranger et al., 1998). Furthermore, expression of these
genes in the developing forelimb (FL) at E14.5 corresponds to
RANKL pathway function in osteoclast differentiation during
bone formation.
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genes during heart valve development was further examined
by in situ hybridization of embryo sections. Interestingly, theseFig. 2. RANKL pathway genes are co-expressed in the developing heart valve endoc
RANKL pathway was assessed by in situ hybridization in E13.5 hearts and E14.5 f
expressed in the endocardium of the developing aortic valves (A, D, G, J; arrowhead
detected in the mesenchymal cells of the remodeling valves (D, E). In addition, co-ex
AoV, aortic valves; AVV, atrioventricular valves; c, chondrocytes.analyses revealed that RANKL, RANK, and Ctsk are co-
expressed with NFATc1 in the developing atrioventricular and
aortic valve endocardium of E13.5 hearts (Fig. 2; arrowheads).ardium and forelimb bone perichondrium. Localized expression of genes in the
orelimbs. RANKL (A–C), RANK (D–F), NFATc1 (G–I), and Ctsk (J–L) are co-
s) and atrioventricular valves (B, E, H, K; arrowheads). RANK expression is also
pression is observed in the perichondrium of E14.5 forelimbs (C, F, I, L; arrows).
Fig. 3. Remodeling valves have endogenous acid phosphatase activity but lack
TRAP activity. Endogenous enzyme activity was examined in cryosections of
snap-frozen unfixed E15.5 embryos. Remodeling valves display non-specific
acid phosphatase activity (red stain) similar to that seen in the developing
humerus of the forelimb (A, C; arrowheads). TRAP-positive cells detected in the
developing humerus are not observed in remodeling valves (B, D; arrows).
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endocardial cells, expression of the receptor RANK is also
apparent in the transformed mesenchymal cells of the
developing valves (Figs. 2D, E). Consistent with the role of
RANKL signaling in bone formation, expression of RANKL,
RANK, NFATc1, and Ctsk is observed in the developing bone
perichondrium of E14.5 forelimbs (Figs. 2C, F, I, L; arrows). In
the developing limbs, these genes are expressed in a subset of
cells surrounding the hypertrophic chondrocytes, a site that is
associated with ossification and osteoclast differentiation later
in development. Although expression of OPG was detected in
the aortic vasculature by in situ hybridization of sections from
E13.5 embryos, it was not observed in the developing heart
valves or bones (data not shown). In the heart, co-expression of
RANKL, RANK, NFATc1, and Ctsk was observed at all stages
valve formation examined (E11.5–E14.5) and in all developing
valve leaflets (pulmonary, aortic, mitral, and tricuspid) (data not
shown). In developing skeletal elements, expression of these
genes is first detected in the developing ribs and forelimbs at
E12.5 and E13.5, respectively (data not shown). Together, these
data demonstrate that components of RANKL signal transduc-
tion are co-expressed in developing bones and heart valves.
Heart valves express acid phosphatase but do not exhibit TRAP
activity or macrophage lineage derivation characteristic of
bone osteoclasts
Since RANKL pathway genes are expressed in colocalized
patterns during formation of the heart valves and bones, further
analysis was performed to determine the extent of the similarity
between the two developing systems. A defining characteristic
of differentiated bone osteoclasts is the presence of TRAP
enzymatic activity. Histochemical analysis for general, non-
specific acid phosphatase enzyme activity and TRAP activity
was performed in parallel on E13.5 and E15.5 embryo sections.
Remodeling valves possess non-specific acid phosphatase
activity comparable to that observed in the developing bones
(Figs. 3A, C and data not shown). The presence of acid
phosphatase activity in the developing valves is indicative of a
low pH environment in the remodeling leaflets, an established
requirement for bone matrix remodeling (Baron et al., 1985;
Karsdal et al., 2005). However, TRAP-positive cells are not
detected in the heart valves and are only observed in developing
bones including the ribs and forelimbs beginning at E15.5 (Figs.
3B, D and data not shown).
Since RANKL promotes differentiation of bone osteoclasts
by inducing NFATc1 in precursor cells derived from macro-
phages, the contribution of macrophages to the embryonic heart
valves was examined. The presence of macrophage cells was
assessed by immunofluorescent antibody staining for the
macrophage-specific surface antigen F4/80, which is first
detected in the developing embryo at E10 (Morris et al.,
1991). In developing bones of the forelimb, F4/80-positive cells
are observed along with NFATc1 and Ctsk-expressing cells in
the pre-osteoclast population in the perichondrium at E13.5,
consistent with the contribution of the macrophage lineage to
osteoclast formation (Figs. 4B, D, F; arrows). In contrast, F4/80-positive cells are not detected in the heart at E10.5, indicating
that macrophages do not contribute to the early stages of valve
formation when NFATc1 is apparent in developing valve
endothelial cells (data not shown) (Ranger et al., 1998). During
heart valve remodeling, F4/80-positive macrophages are still not
present in the heart of E13.5 embryos in association with valve
endocardial cells expressing NFATc1 and Ctsk (Figs. 4A, C, E).
To further demonstrate the lack of macrophage lineage
contribution to the remodeling valves, hearts from PU.1−/−
embryos were examined. Homozygous null mutation of PU.1
results in the failure to establish the macrophage lineage
evidenced by lack of F4/80 expression (Fig. 4H) (McKercher
et al., 1996). Despite macrophage lineage deficiency, valve
leaflet formation and expression of RANKL, RANK, NFATc1,
and Ctsk appear normal in E13.5 PU.1−/− embryos (Fig. 4J
and data not shown). Thus, macrophage cells are not normally
detected in the heart during early stages of valve formation,
and their absence does not affect gene expression in the
remodeling leaflet. The consistent absence of F4/80 expressing
cells in the developing valves along with unaltered gene
expression in hearts of macrophage deficient PU.1−/− embryos
demonstrates that valve endocardial expression of RANKL
pathway genes is not dependent on the presence of macro-
phages. Together, these data show that macrophage lineage
progenitors and TRAP activity are distinct characteristics of
bone osteoclasts that are not associated with the presence of
the RANKL system in the developing heart valves.
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is dependent on NFATc1
The requirement of NFATc1 for endocardial expression of
RANKL pathway genes during heart valve remodeling was
examined using NFATc1−/− embryos. In situ hybridization of
sections from E12.5 embryos shows that Ctsk expression is
notably decreased in the developing valves of NFATc1−/− hearts
relative to control littermates, consistent with direct transcrip-tional regulation of Ctsk by NFATc1 (Figs. 5C, D; arrowheads)
(Matsumoto et al., 2004). Interestingly, expression of RANKL in
the developing valves of homozygous NFATc1 null hearts is also
visibly reduced compared to control hearts, suggesting that
NFATc1 contributes to cardiac expression of RANKL (Figs. 5A,
B; arrowheads). A variable reduction in Ctsk and RANKL gene
expression was also observed in the perichondrium of the
developing rib and forelimb bones of E12.5–E13.5 NFATc1−/−
embryos (data not shown). As a control, expression of Mmp2
was examined to determine if expression of a gene independent
from the RANKL pathway is affected by loss of NFATc1.
Consistent with its reported contribution to EMT (Alexander
et al., 1997; Song et al., 2000), Mmp2 is expressed in both the
endocardium and mesenchyme of developing valves. Notably,
Mmp2 expression in the valves is not overtly affected in
NFATc1−/− hearts (Figs. 5E, F), indicating that the reduced
expression of Ctsk and RANKL in NFATc1−/− hearts is not due to
a generalized loss of gene expression during valve formation in
null embryos. Furthermore, unaltered expression of Mmp2 in
NFATc1 deficient hearts is consistent with normal progression
of EMT in NFATc1−/− embryos (de la Pompa et al., 1998;
Ranger et al., 1998). Decreased expression of RANKL and Ctsk
along with unaltered Mmp2 expression was equally apparent in
the semilunar and the atrioventricular valves of E12.5–E13.5
NFATc1−/− embryos (data not shown).
In accordance with the results obtained by in situ
hybridization, quantitative real time RT-PCR also shows that
Ctsk expression is significantly decreased in whole hearts from
E12.5 NFATc1−/− embryos relative to wild-type or heterozygous
controls, whereas cardiac expression of Mmp2 is unchanged
between genotypes (Fig. 5G). In addition to decreased Ctsk
transcript levels, a clear reduction in Ctsk protein is also
detected in valve endothelial cells of NFATc1−/− hearts. In
NFATc1+/+ hearts, punctate intracellular Ctsk protein expression
is detected in NFATc1-expressing endocardial cells of the
developing tricuspid valve (Figs. 5H, J). In contrast, loss of
NFATc1 expression in homozygous null embryos results in a
concomitant loss of endocardial Ctsk expression (Figs. 5I, K).
Together, these results demonstrate that expression of RANKL
and Ctsk in the developing valve endocardium is dependent onFig. 4. Endocardial cells of the valve primordia expressing NFATc1 and Ctsk are
not derived from the macrophage lineage. Fluorescent confocal microscopy for
the macrophage marker F4/80 (A, B), NFATc1 (C, D), and Ctsk (E, F). F4/80-
positive macrophages are not detected in developing heart valves, whereas
endocardial cells express NFATc1 and Ctsk (A, C, E; arrows). The same results
were observed in all valves, and representative images of aortic valves (AoV) are
shown. In comparison, F4/80-positive cells are observed along with NFATc1-
and Ctsk-positive pre-osteoclast cells in the developing forelimb perichondrium
(B, D, F; arrows), consistent with a macrophage lineage contribution to
osteoclast differentiation in bone. Insets show enhanced images of cells indicated
by arrows (B, left arrow; F, right arrow). Note membrane expression of F4/80 (B)
and punctate intracellular expression of Ctsk (E, F). (G–J) Valve formation and
endocardial gene expression are not affected in macrophage deficient PU.1−/−
embryos at E13.5. (G, H) Immunofluorescent confocal images of the developing
vertebrae demonstrate the absence of F4/80-positive macrophages in PU.1−/−
embryos (H) in comparison to PU.1+/+ embryos (G; arrows). In situ
hybridization of aortic valves from PU.1+/+ and PU.1−/− embryos shows that
valve leaflet formation andCtsk gene expression are not altered in E13.5 PU.1−/−
embryos despite macrophage lineage deficiency (I, J; arrowheads).
Fig. 5. Ctsk and RANKL gene expression in the developing valves is dependent on NFATc1. (A–F) In situ hybridization of E12.5 NFATc1+/− (A, C, E) and NFATc1−/−
(B, D, F) embryo sections with probes for RANKL (A, B), Ctsk (C, D), and Mmp2 (E, F). Endocardial expression of RANKL and Ctsk is notably decreased in the
developing valves of NFATc1−/− hearts compared to a heterozygous control littermate (A–D; arrowheads). Mmp2 expression is detected in both the endocardial and
mesenchymal cells of the developing valves and is not affected in NFATc1−/− hearts, indicating that there is not a generalized reduction in gene expression in the null
hearts. (G) Quantitative real time RT-PCR analysis of gene expression in E12.5 whole hearts. Ctsk expression is significantly decreased in NFATc1−/− hearts relative to
NFATc1+/+ and NFATc1+/− hearts, whereas Mmp2 expression is not altered between genotypes. The graph represents the average expression ± the standard error
relative to NFATc1+/+ hearts from three experiments. The asterisk represents statistical significance of observed differences as determined by Student's t test (P b 0.01).
(H–K) Immunofluorescent confocal images of adjacent AV valve sections (tricuspid valve) from E12.5 NFATc1+/+ (H, J) and NFATc1−/− (I, K) hearts. NFATc1+/+
hearts show co-expression of NFATc1 (red) and Ctsk (green) in the valve endocardium (H, J; arrowheads). Targeted deletion of NFATc1 expression in null embryos
results in a concomitant loss of Ctsk protein expression in the developing valves (I, K; arrowheads).
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by NFATc1 involves transcriptional activation of matrix
degrading enzymes including Ctsk.
RANKL treatment affects NFATc1 and Ctsk gene expression in
whole heart organ cultures
In order to gain insight into the effect of RANKL on cardiac
expression of NFATc1 and Ctsk during heart valve development,
isolated whole hearts from E10.5 embryos were maintained inorgan culture for 24 h in the presence or absence of rhRANKL.
Quantitative real time RT-PCR reveals elevated NFATc1 and
Ctsk expression levels in hearts from normal embryos cultured in
the presence of RANKL relative to vehicle control treated hearts
(Fig. 6A). In contrast, Mmp2 expression is not affected by
rhRANKL treatment (Fig. 6A), demonstrating that the aug-
mented expression of NFATc1 and Ctsk is a specific response to
RANKL treatment. Thus, RANKL can stimulate expression of
NFATc1 and Ctsk in the heart during early stages of heart valve
development.
Fig. 6. RANKL treatment augments NFATc1 and Ctsk gene expression in whole heart organ cultures. Hearts from E10.5 nontransgenic or NFATc1 targeted embryos
were cultured for 24 h in the presence or absence of 100 ng/ml rhRANKL. (A) Quantitative real time RT-PCR shows that RANKL treatment stimulates NFATc1
(1.91x ± 0.45) and Ctsk (1.39x ± 0.12) expression in nontransgenic hearts relative to vehicle control treated hearts. In NFATc1−/− cultured hearts, Ctsk is significantly
reduced despite RANKL treatment. In comparison,Mmp2 gene expression is not significantly altered between the different culture conditions. The graph represents the
average expression ± the standard error relative to nontransgenic vehicle control hearts, and asterisks represent statistical significance as determined by Student's t test
(P b 0.05). (B) Linear range RT-PCR for NFATc1, Ctsk, and L7 on two independent samples from each experimental condition. (C–H) Serial sections (5 μm) of outflow
tract endocardial cushions from control (C, E, G) or RANKL-treated (D, F, H) cultured hearts. Endocardial expression of NFATc1 (E–F) and Ctsk (G–H) appears
enhanced with RANKL treatment compared to vehicle treated hearts (E–H; arrowheads). In adjacent sections, mesenchymal cells in outflow tract cushions of RANKL-
treated hearts showed occasional ectopic NFATc1 transcript (F; arrows) and protein (D; arrows) in comparison to endocardial restricted expression in control hearts.
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the presence of RANKL to determine the requirement of
NFATc1 in RANKL-mediated induction of Ctsk. Although a
low level of NFATc1 transcripts is still detected in hearts from
NFATc1 homozygous null embryos, these transcripts are not
translated (see Fig. 5I). Notably, Ctsk expression is
significantly reduced in cultured NFATc1−/− hearts despite
treatment with RANKL (Fig. 6A). In comparison, Mmp2
expression levels are not significantly altered in RANKL-
treated hearts from NFATc1 deficient embryos (Fig. 6A).
Linear range RT-PCR was also performed for NFATc1, Ctsk,
and L7 and was used to visualize increased NFATc1 and Ctsk
expression in the presence of RANKL as well as decreasedgene expression in RANKL-treated NFATc1−/− cultured hearts
(Fig. 6B).
In situ hybridization of serial sections from cultured hearts
further corroborates the observed effects of RANKL treatment on
NFATc1 and Ctsk gene expression. Augmented expression of
NFATc1 is detected in the outflow tract cushions of hearts treated
with RANKL compared to a vehicle control heart (Figs. 6E, F;
arrowheads). Furthermore, RANKL treatment induced occasion-
al ectopic NFATc1-positive cells in the cushion mesenchyme. In
serial sections, colocalized expression of NFATc1 transcript and
protein is observed in cushion mesenchymal cells of RANKL-
treated hearts compared to endocardial restricted expression in
control hearts (Figs. 6C–F; arrows). Sections from control or
415A.W. Lange, K.E. Yutzey / Developmental Biology 292 (2006) 407–417RANKL-treated hearts show low level Ctsk expression in the
endocardium of outflow tract cushions (Figs. 6G, H; arrow-
heads). In RANKL-treated hearts, endocardial cells with strong
NFATc1 expression also show an increase in Ctsk expression
relative to vehicle treated hearts (Figs. 6E–H). Thus, RANKL
can stimulate cardiac expression ofNFATc1 and Ctsk during early
stages of heart valve development, and the RANKL-mediated
induction of Ctsk expression is dependent on NFATc1.
Discussion
During heart valve morphogenesis, remodeling of the
primitive endocardial cushions into mature valve leaflets is
critical for advanced heart development and function. This
process requires calcineurin/NFATc1 signaling in the endocar-
dium following EMT (Chang et al., 2004; de la Pompa et al.,
1998; Ranger et al., 1998), however, the regulatory pathways
that govern NFATc1-dependent valve remodeling have not been
defined. Studies which identified NFATc1 as a critical
transcriptional regulator of bone remodeling enzymes such as
Ctsk and TRAP during RANKL-mediated osteoclast differen-
tiation provided insight into a signaling pathway by which
NFATc1 regulates matrix remodeling events (Hirotani et al.,
2004; Ikeda et al., 2004; Ishida et al., 2002; Matsumoto et al.,
2004; Matsuo et al., 2004; Takayanagi et al., 2002).
Investigation of this signaling cascade during valvulogenesis
shows that RANKL pathway genes are expressed in the
remodeling heart valves, that RANKL and Ctsk expression in the
valve endocardium is dependent on NFATc1, and that RANKL
treatment can induce NFATc1 and Ctsk expression.
Despite the established requirement for calcineurin/NFATc1
signaling during heart valve development, the critical regulators
of calcineurin activation and NFATc1 nuclear translocation
during valve remodeling have not been well characterized.
While VEGF can stimulate calcineurin-dependent NFATc1
nuclear translocation in cultured adult human pulmonary valve
endothelial cells, it remains to be determined whether VEGF
signaling can induce NFATc1 activation in the endocardium
during embryonic heart valve remodeling (Johnson et al., 2003).
In this study, we find evidence that RANKL signaling is
upstream of NFATc1 during heart valve remodeling. Interest-
ingly, expression of RANKL in the developing valves is also
dependent on NFATc1, indicating that RANKL expression is
subject to feedback regulation by NFATc1. Although expression
of RANKL during bone development is not affected by
inhibition of calcineurin/NFATc signaling, induction of
RANKL in activated T-cells is regulated by Ca2+ signals and
can be blocked by the calcineurin inhibitor cyclosporin A,
consistent with calcineurin/NFATc-dependent regulation of
RANKL expression (Koga et al., 2005; Wang et al., 2001,
2002). Thus, the interaction between RANKL and NFATc1
during heart valve development likely involves complex
positive and negative feedback regulatory mechanisms.
Defining the exact functional requirements for NFATc1 during
heart development has been limited by the lack of identified
downstream target genes relevant to valve leaflet remodeling.
Although NFATc1 is required for osteoclast differentiation andheart valve formation, the regulatory requirements for NFATc1 in
each system are not the same. During osteoclast differentiation,
PU.1 cooperates with NFATc1 to directly regulate Ctsk gene
expression and NFATc1 directly activates the TRAP promoter
(Matsumoto et al., 2004; Takayanagi et al., 2002). However,
PU.1 does not appear to contribute to endocardial expression of
Ctsk and cells possessing TRAP enzymatic activity are not
detected in the developing valves, indicating that NFATc1 does
not promote TRAP expression during valve formation. Thus,
there are distinct differences in the regulatory mechanisms that
control Ctsk expression and promote TRAP expression in
osteoclasts versus the valve endocardium. Notably, the results
from the present study show that expression of Ctsk in the valve
endocardium during stages of leaflet remodeling is dependent on
NFATc1. In a poorly understood process during valvulogenesis,
the primitive endocardial cushions are remodeled into thin valve
leaflets that contain an organized extracellular matrix comprised
primarily of collagen and elastin (Icardo and Colvee, 1995;
Missirlis and Armeniades, 1977). As collagen and elastin are
substrates of Ctsk, it will be interesting to determine if Ctsk
contributes to the remodeling and organization of these
extracellular matrix components during heart valve maturation
(Bossard et al., 1996; Garnero et al., 1998).
Although the results of this study indicate that RANKL
signaling and Ctsk are associated with valve remodeling in the
embryonic heart, mice with targeted inactivation of RANKL,
RANK, OPG, or Ctsk are viable and have no reported defects in
valve formation (Bucay et al., 1998; Fata et al., 2000; Gowen
et al., 1999; Kong et al., 1999; Li et al., 2000; Mizuno et al.,
1998). Since valve development in these mice is not as
severely compromised as in NFATc1−/− embryos, it is likely
that additional signals are involved in activation of calci-
neurin/NFATc1 signaling in the valve endocardium. Further-
more, the lack of any reported valve anomalies in humans
with pycnodysostosis, resulting from mutations in Ctsk,
indicates that additional matrix remodeling enzymes likely
contribute to proper leaflet formation (Gelb et al., 1996;
Johnson et al., 1996). Interestingly, mice with homozygous
null mutation of TNF-α converting enzyme (TACE) have
abnormal valve remodeling resulting in enlarged leaflets, and
TACE has been implicated in the functional regulation of
RANKL via proteolytic release from the plasma membrane
(Horiuchi et al., 2005; Jackson et al., 2003; Lum et al., 1999).
In addition, calcineurin/NFATc1 signaling is activated in
response to acidosis, and remodeling heart valves have
endogenous acid phosphatase activity, indicating that acidifi-
cation may also contribute to activation of calcineurin/NFATc1
signaling during valve remodeling (Komarova et al., 2005).
Thus, identifying the regulatory interactions between pathways
that intersect with calcineurin/NFATc1 signaling in the valve
endocardium will provide a better understanding of the
molecular mechanisms that control valve leaflet remodeling.
The presence of the RANKL signaling pathway during heart
valve development has provided new insight into a regulatory
mechanism underlying NFATc1-dependent valve remodeling.
Interestingly, the RANKL system has also been implicated in
cellular remodeling events during calcification of the adult
416 A.W. Lange, K.E. Yutzey / Developmental Biology 292 (2006) 407–417valves and vasculature (Collin-Osdoby, 2004; Kaden et al.,
2004, 2005; Vattikuti and Towler, 2004). However, further
detailed mechanistic studies are necessary to define RANKL
pathway function in relation to NFATc1 during valve leaflet
formation as well as pathogenetic calcification processes.
Malformations of the valves are common congenital heart
defects, and recent studies indicate a genetic basis for valvular
heart disease (Garg et al., 2005; Hoffman and Kaplan, 2002;
Horne et al., 2004). Therefore, defining the molecular
mechanisms that govern valve leaflet formation has significant
implications toward understanding the etiology of congenital
valve anomalies as well as for adult valve disease.
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